The estimated Net Worth of Rafael Amado is at least $9.24 Milione dollars as of 12 August 2024. Rafael Amado owns over 3,115 units of Allogene Therapeutics Inc stock worth over $59,413 and over the last 9 years he sold ALLO stock worth over $1,724,522. In addition, he makes $7,452,160 as Executive Vice President - Research and Development e Chief Medical Officer at Allogene Therapeutics Inc.
Rafael has made over 15 trades of the Allogene Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 3,115 units of ALLO stock worth $50,463 on 12 August 2024.
The largest trade he's ever made was exercising 42,000 units of Allogene Therapeutics Inc stock on 29 December 2023 worth over $122,220. On average, Rafael trades about 4,075 units every 64 days since 2016. As of 12 August 2024 he still owns at least 20,417 units of Allogene Therapeutics Inc stock.
You can see the complete history of Rafael Amado stock trades at the bottom of the page.
Dr. Rafael G. Amado M.D. serves as Executive Vice President - Research and Development, Chief Medical Officer of the Company. Prior to joining us, Dr. Amado served as President, Research & Development, at Adaptimmune Therapeutics plc from August 2018 to August 2019 and as Chief Medical Officer at Adaptimmune from March 2015 to August 2018. He has over 15 years of experience within the biotech and pharmaceutical industries. Dr. Amado formerly served as Senior Vice President and Head of Oncology R&D at GSK, where he was responsible for integrating oncology R&D activities, from drug target identification to clinical development and registration globally. During his tenure, Dr. Amado oversaw in the development of numerous products across multiple geographies. Prior to joining GSK, Dr. Amado was Executive Director of Therapeutic Oncology at Amgen where he was responsible for development activities of several assets, including the development of products in molecularly characterized tumors. Dr. Amado trained as a Hematologist/Oncologist at the University of California, Los Angeles, where he remained as faculty until joining Amgen. He holds an M.D. from the University of Seville School of Medicine, and performed his residency in Internal Medicine at Michael Reese Hospital, a formerly University of Chicago Affiliated Hospital, and his fellowship in Hematology/Oncology at the University of California, Los Angeles.
As the Executive Vice President - Research and Development e Chief Medical Officer of Allogene Therapeutics Inc, the total compensation of Rafael Amado at Allogene Therapeutics Inc is $7,452,160. There are 1 executives at Allogene Therapeutics Inc getting paid more, with David Chang having the highest compensation of $11,192,100.
Rafael Amado is 56, he's been the Executive Vice President - Research and Development e Chief Medical Officer of Allogene Therapeutics Inc since 2019. There are 10 older and 10 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Rafael's mailing address filed with the SEC is 5 Ashwood Ln, Malvern, PA 19355, USA.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over $137,494,387 worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth $29,333,135 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Arie Belldegrun e Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $286,894. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth $42,501.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: